Thus, the conversion of TLR4 activation from antitumor to protumor activity by agonists—which depends on a variety of criteria, including timing, duration, and strength—remains a challenging issue for scientists studying tumor immunotherapy.220, 223, 228, 245, 247. This evidence concerns the gene TLR4 and neoplasm.